Truist Securities Maintains Buy on Praxis Precision Medicine, Raises Price Target to $500

Benzinga · 2d ago
Truist Securities analyst Joon Lee maintains Praxis Precision Medicine (NASDAQ:PRAX) with a Buy and raises the price target from $360 to $500.